Quantcast

Industry news that matters to you.  Learn more

Lupus Experts Gather at the FDA to Explore Potential for Biomarkers to Accelerate Clinical Trials

Biomarkers, potential indicators to monitor disease progress and treatment success, are among the most challenging and critical areas of lupus research according representatives of industry, academia, government and advocacy attending a U.S. Food and Drug Administration workshop this week. The meeting was convened to focus on the development of biomarkers to predict acute worsening of disease, called a flare, and their potential for accelerating lupus clinical trials and new drug approvals.